微创脑科学(02172)今日盘中大跌7.25%,引发市场关注。截至上午9点46分,该股报价11.38港元,较月内高点15.24港元已下跌约25%。
消息面上,微创脑科学刚刚发布了2024年度业绩报告。报告显示,公司全年收入达7.62亿元人民币,同比增长14.44%;权益股东应占溢利为2.54亿元,同比大幅增长74.63%。每股基本盈利为0.44元,公司拟派发末期股息每股0.11港元。业绩增长主要得益于海外业务的突破性进展,报告期内海外收入同比增长137.6%。此外,脑动脉粥样硬化狭窄产品市场份额提升、弹簧圈产品受益于集采中标,以及多款新获批的急性缺血性脑卒中产品加速推广,都对收入增长做出了贡献。
尽管年度业绩表现亮眼,微创脑科学股价仍出现大幅下跌。分析人士认为,这可能是由于投资者对公司未来增长预期或市场条件存在担忧,也可能是近期股价涨幅较大后的获利回吐。市场将继续关注该公司后续发展及股价走势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.